AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017
Jul 21, 2017
29864_dirs_2017-07-21_2758a94d-9a8e-4337-8a50-e22970584279.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-07-19
Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-07-19 | Common Stock | M | 6303 | $96.87 | Acquired | 128814 | Direct |
| 2017-07-19 | Common Stock | M | 32343 | $109.14 | Acquired | 161157 | Direct |
| 2017-07-19 | Common Stock | S | 39833 | $161.00 | Disposed | 121324 | Direct |
| 2017-07-21 | Common Stock | S | 700 | $158.08 | Disposed | 120624 | Direct |
| 2017-07-21 | Common Stock | S | 1000 | $158.92 | Disposed | 119624 | Direct |
| 2017-07-21 | Common Stock | S | 400 | $159.85 | Disposed | 119224 | Direct |
| 2017-07-21 | Common Stock | S | 3464 | $161.38 | Disposed | 115760 | Direct |
| 2017-07-21 | Common Stock | S | 1336 | $162.04 | Disposed | 114424 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-07-19 | Stock Option (Right to Buy) | $96.87 | M | 6303 | Disposed | 2024-07-14 | Common Stock (6303) | Direct |
| 2017-07-19 | Stock Option (Right to Buy) | $109.14 | M | 32343 | Disposed | 2025-02-02 | Common Stock (32343) | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $158.08 (range $157.48 to $158.41).
F3: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $158.92 (range $158.61 to $159.48).
F5: Open market sales reported on this line occurred at a weighted average price of $159.85 (range $159.64 to $160.25).
F6: Open market sales reported on this line occurred at a weighted average price of $161.38 (range $160.90 to $161.89).
F7: Open market sales reported on this line occurred at a weighted average price of $162.04 (range $161.90 to $162.38).
F8: The option vests in 16 quarterly installments from 7/15/2014.
F9: The option vests in 16 quarterly installments from 2/3/2015.